Kaposi Sarcoma–Associated Herpesvirus Infection and Complications Among Solid Organ Transplant Recipients — United States, January 2021–September 2025

January 1, 2026
Case Report
Ian Kracalik, PhD, Pallavi Annambhotla, DrPH, David W. McCormick, MD, Andrew I. Geller, MD, Kelsey McDavid, MPH, Isabel Griffin, PhD, Raymond Lynch, MD, Brianna Doby, MPH, Yoichiro Natori, MD, Sofya Tokman, MD, Christine M. Durand, MD, Camille N. Kotton, MD, Emily Blumberg, MD, Ricardo M. La Hoz, MD, Lauri A. Hicks, DO, Stephanie M. Pouch, MD, Sridhar V. Basavaraju, MD, Donor-Derived KSHV Investigation Group
Pathogen:Kaposi Sarcoma–Associated Herpesvirus
Infection Type:Viral infection leading to Kaposi sarcoma and lymphoproliferative disorders
Pathogen Type:Virus

Summary

This report details a significant increase in Kaposi Sarcoma–Associated Herpesvirus (KSHV) infections and complications among solid organ transplant recipients in the United States between January 2021 and September 2025. Forty-six deceased donors were suspected of transmitting KSHV, leading to 74 (48%) of 153 recipients developing post-transplantation KSHV infection. Clinical presentations included Kaposi sarcoma (61%), lymphoproliferative disorders (14%), and KSHV inflammatory cytokine syndrome (8%), with 25 (16%) recipient deaths. Most donors and recipients were HIV-negative, but two-thirds of donors had a history of nonmedical drug use, indicating a changing risk profile for KSHV transmission. Diagnosis relied on molecular, serologic, or immunohistochemical assays.

Key note: Clinicians must maintain a high index of suspicion for KSHV in transplant recipients, especially with donor risk factors like nonmedical drug use, to facilitate prompt diagnosis and management.

DOI: 10.15585/mmwr.mm7508a1